Goldman Sachs and Invesco Perpetual have signed on as new investors in Circassia, a UK biotech exploring ways to control immune responses. They helped put up $21.8 million in Circassia's second round of venture capital. Circassia's lead products target allergies using its T-cell epitope desensitization technology, which was originally developed at Imperial College London.
"We have made good progress advancing our anti-allergy products during the last year, and successfully completing this funding, particularly in the current challenging market conditions, is a strong vote of confidence from a syndicate of world-class investors," says Steve Harris, Circassia's CEO.
- check out the release for more